Adalimumab biosimilar (AXXO)

阿达木单抗生物类似药 (AXXO)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (AXXO)
Drug Alias Name阿达木单抗生物仿制药 (AXXO)Adalimumab follow-on biologicadalimumab follow-on biologic
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidArthritis, Psoriatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesAxxo
China Registration ClassN/A

Develop Information

Active CompaniesAxxo
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidArthritis, Psoriatic
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A